United Therapeutics Corporation (NASDAQ: UTHR) and XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (STO: XVIVO), today announced that the use of XVIVO’s ex-vivo lung perfusion (EVLP) technology will be incorporated into the Silver Spring, Maryland laboratory of Lung Bioengineering Inc., a subsidiary of United Therapeutics’ public benefit corporation subsidiary Lung Biotechnology PBC.
{iframe}https://www.streetinsider.com/Management+Comments/United+Therapeutics+%28UTHR%29+Announces+Collaboration+with+XVIVO+Perfusion+to+Reduce+Organ+Shortage/14296458.html{/iframe}